Symphogen A/S (Lyngby, Denmark) is a clinical-stage biopharmaceutical company developing recombinant antibody mixtures: a new class of antibody therapeutics for the treatment of oncology.

The development of antibody mixtures represents a significant opportunity to optimize for both antibody diversity and specificity, thereby capturing the optimal characteristics of the natural human immune response.

Symphogen has entered into several partnerships with pharmaceutical companies in the US, Europe, and Japan.

For more information, please contact:

Søren Lemonius, Msc

Managing General Partner

Phone: +45 4081 4889